These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37797454)

  • 1. Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019-2022).
    He Y; Su Q; Zhao L; Zhang L; Yu L; Shi J
    Bioorg Chem; 2023 Dec; 141():106869. PubMed ID: 37797454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biased Opioid Ligands.
    Faouzi A; Varga BR; Majumdar S
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of more effective and safer analgesics for pain management.
    Turnaturi R; Chiechio S; Salerno L; Rescifina A; Pittalà V; Cantarella G; Tomarchio E; Parenti C; Pasquinucci L
    Eur J Med Chem; 2019 Dec; 183():111701. PubMed ID: 31550662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.
    Kaski SW; White AN; Gross JD; Siderovski DP
    Anesth Analg; 2021 Feb; 132(2):406-419. PubMed ID: 33332902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.
    Ananthan S
    AAPS J; 2006 Mar; 8(1):E118-25. PubMed ID: 16584118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Insights into Mu Opioid Pharmacology.
    Pasternak GW; Childers SR; Pan YX
    Handb Exp Pharmacol; 2020; 258():89-125. PubMed ID: 31598835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.
    Schmidhammer H; Erli F; Guerrieri E; Spetea M
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33147885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.
    Huang H; Wang W; Xu X; Zhu C; Wang Y; Liu J; Li W; Fu W
    Eur J Med Chem; 2020 Mar; 189():112070. PubMed ID: 31982651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biased ligands at opioid receptors: Current status and future directions.
    Che T; Dwivedi-Agnihotri H; Shukla AK; Roth BL
    Sci Signal; 2021 Apr; 14(677):. PubMed ID: 33824179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bifunctional μ opioid and σ
    Zhuang T; Xiong J; Hao S; Du W; Liu Z; Liu B; Zhang G; Chen Y
    Eur J Med Chem; 2021 Nov; 223():113658. PubMed ID: 34175542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacement of current opioid drugs focusing on MOR-related strategies.
    Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
    Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivity of new mu and delta opioid peptides.
    Capasso A
    Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice.
    Simonin F; Slowe S; Becker JA; Matthes HW; Filliol D; Chluba J; Kitchen I; Kieffer BL
    Eur J Pharmacol; 2001 Mar; 414(2-3):189-95. PubMed ID: 11239918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.
    Brissett DI; Whistler JL; van Rijn RM
    Eur J Pain; 2012 Mar; 16(3):327-37. PubMed ID: 22337177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel GPCR paradigms at the μ-opioid receptor.
    Thompson GL; Kelly E; Christopoulos A; Canals M
    Br J Pharmacol; 2015 Jan; 172(2):287-96. PubMed ID: 24460711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.
    Matthes HW; Smadja C; Valverde O; Vonesch JL; Foutz AS; Boudinot E; Denavit-Saubié M; Severini C; Negri L; Roques BP; Maldonado R; Kieffer BL
    J Neurosci; 1998 Sep; 18(18):7285-95. PubMed ID: 9736649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics.
    McLaughlin JP; Rayala R; Bunnell AJ; Tantak MP; Eans SO; Nefzi K; Ganno ML; Dooley CT; Nefzi A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mu Opioid Receptor Heterodimers Emerge as Novel Therapeutic Targets: Recent Progress and Future Perspective.
    Zhang L; Zhang JT; Hang L; Liu T
    Front Pharmacol; 2020; 11():1078. PubMed ID: 32760281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
    Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
    J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for developing μ opioid receptor agonists with reduced adverse effects.
    Yuan Y; Xu T; Huang Y; Shi J
    Bioorg Chem; 2024 Aug; 149():107507. PubMed ID: 38850778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.